On March 12, 2026, Seres Therapeutics, Inc. announced its financial results for Q4 and the full year 2025, highlighting a net income of $5.7 million compared to a net loss of $125.8 million in 2024. The company is focusing on advancing its live biotherapeutic programs.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.